DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 101–200 of 1,000
Andersson, M., Balkhed, Å. Ö., Fredrikson, M. G., Holmbom, M., Hällgren, A., Berg, S., & Hanberger, H. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03529-8 · Cited by 91
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients
Al‐Shaer, M. H., Rubido, E., Cherabuddi, K., Venugopalan, V., Klinker, K. P., & Peloquin, C. A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa359 · Cited by 85
Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
Abdul-Aziz, M. H., Brady, K., Cotta, M. O., & Roberts, J. A. (2022) · PubMed · doi:10.1097/ftd.0000000000000940 · Cited by 48
Self-citationUltrafast quantification of β-lactam antibiotics in human plasma using UPLC–MS/MS
Carlier, M., Stove, V. V., Waele, J. J. D., & Verstraete, A. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.11.034 · Cited by 81
Ehmann, L., Zöller, M., Minichmayr, I. K., Scharf, C., Maier, B., Schmitt, M. V., Hartung, N., Huisinga, W., Vogeser, M., Frey, L., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1829-4 · Cited by 81
“Adequate antibiotic exposure not only has been found to improve clinical success but also has been suggested to reduce resistance development [6, 7].”
BackgroundGrau, S., Luque, S., Campillo, N., Samsó, E., Rodriguez, U. G.-D., García-Bernedo, C. A., Salas, E., Sharma, R., Hope, W. W., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv173 · Cited by 83
Self-citationGatti, M., Cojutti, P. G., Pascale, R., Tonetti, T., Laici, C., Dell’Olio, A., Siniscalchi, A., Giannella, M., Viale, P., & Pea, F. (2021) · Antibiotics · doi:10.3390/antibiotics10111311 · Cited by 88
“However, emerging clinical data suggest that more aggressive PK/PD targets up to 100%fT>4–5×MIC may give rise to better outcomes in critically ill patients [6,8,9].”
BackgroundCharmillon, A., Novy, E., Agrinier, N., Léone, M., Kimmoun, A., Lévy, B., Demoré, B., Dellamonica, J., & Pulcini, C. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.04.019 · Cited by 79
Udy, A. A., Roberts, J. A., Lipman, J., & Blot, S. I. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.019 · Cited by 83
Self-citationRoberts, J. A., Stove, V. V., Waele, J. J. D., Sipinkoski, B., McWhinney, B. C., Ungerer, J. P. J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, K.-M., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.023 · Cited by 76
Self-citationStrategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)
Bretonnière, C., Léone, M., Milési, C., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3853-7 · Cited by 80
Self-citationMinichmayr, I. K., Roberts, J. A., Frey, O. R., Roehr, A. C., Kloft, C., & Brinkmann, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx526 · Cited by 75
Self-citationRoberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., Kirkpatrick, C. M. J., Krüger, P., Roberts, M. S., & Lipman, J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku564 · Cited by 79
Self-citationBurger, R., Guidi, M., Calpini, V., Lamoth, F., Decosterd, L. A., Robatel, C., Buclin, T., Csajka, C., & Marchetti, O. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky370 · Cited by 76
Antibiotic exposure at the site of infection: principles and assessment of tissue penetration
Jager, N. G. L., van Hest, R. M., Lipman, J., Roberts, J. A., & Cotta, M. O. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1621161 · Cited by 74
Self-citationBlassmann, U., Roehr, A. C., Frey, O. R., Vetter‐Kerkhoff, C., Thon, N., Hope, W. W., Briegel, J., & Huge, V. (2016) · Critical Care · doi:10.1186/s13054-016-1523-y · Cited by 80
“These findings are concordant with those derived from previous studies in which researchers have also described large interindividual variability in meropenem concentrations in serum [17] and CSF [18].”
ResultDose optimization of piperacillin/tazobactam in critically ill children
Cock, P. A. J. G. D., van Dijkman, S. C., Jaeger, A. D., Willems, J., Carlier, M., Verstraete, A., Delanghe, J., Robays, H., Walle, J. V., Pasqua, O. E. D., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx093 · Cited by 78
Scharf, C., Paal, M., Schroeder, I., Vogeser, M., Draenert, R., Irlbeck, M., Zöller, M., & Liebchen, U. (2020) · Antibiotics · doi:10.3390/antibiotics9030131 · Cited by 72
Antibiotic stewardship in the ICU: time to shift into overdrive
Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., Hékimian, G., & Luyt, C.-E. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01134-9 · Cited by 56
Barbier, F., Hraiech, S., Kernéis, S., Veluppillai, N., Pajot, O., Poissy, J., Roux, D., & Zahar, J. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01153-6 · Cited by 74
Surviving Sepsis Guidelines 2012
Vassalos, A., & Rooney, K. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31829644e8 · Cited by 70
Zander, J., Döbbeler, G., Nagel, D., Maier, B., Scharf, C., Huseyn‐Zada, M., Jung, J., Frey, L., Vogeser, M., & Zöller, M. (2016) · Critical Care · doi:10.1186/s13054-016-1255-z · Cited by 68
“5 mg/ L trough level corresponds to a percentage of time above the minimal inhibitory concentration (%T >MIC) of 100 % [13, 14] using a MIC value of 16 mg/L [6, 14, 18] and taking into account an average protein-binding fraction of 30 % [12, 19–22].”
BackgroundMethodBéranger, A., Benaboud, S., Urien, S., Moulin, F., Bille, E., Lesage, F., Zheng, Y., Genuini, M., Gana, I., Renolleau, S., et al. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0682-1 · Cited by 68
Ehmann, L., Zoller, M., Minichmayr, I. K., Scharf, C., Huisinga, W., Zander, J., & Kloft, C. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.06.016 · Cited by 67
Lanckohr, C., & Bracht, H. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000967 · Cited by 75
la Martire, G., Robin, C., Oubaya, N., Lepeule, R., Beckerich, F., Leclerc, M., Barhoumi, W., Toma, A., Pautas, C., Maury, S., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3328-1 · Cited by 70
Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?
Abdul-Aziz, M. H., & Roberts, J. A. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000810 · Cited by 67
“Antibiotic dosing that maximizes the attainment of optimal pharmacokinetic/pharmacodynamic indices increases the likelihood of therapeutic response and positive patient outcomes [12,13].”
BackgroundSelf-citationAntimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation
Shekar, K., Abdul-Aziz, M. H., Cheng, V., Burrows, F. S., Buscher, H., Cho, Y., Corley, A., Diehl, A., Gilder, E., Jakob, S. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1393oc · Cited by 66
Self-citationContinuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory
Grupper, M., Kuti, J. L., & Nicolau, D. P. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-16 · Cited by 72
Decosterd, L. A., Mercier, T., Ternon, B., Cruchon, S., Guignard, N., Lahrichi, S., Pesse, B., Rochat, B., Burger, R., Lamoth, F., et al. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122160 · Cited by 71
Scharf, C., Liebchen, U., Paal, M., Taubert, M., Vogeser, M., Irlbeck, M., Zöller, M., & Schroeder, I. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00504-w · Cited by 65
“5 [16, 1359] 92 [52, 850] 64 [16, 1359] 61 [25, 693]”
BackgroundMethodInfluentialKristoffersson, A., David‐Pierson, P., Parrott, N. J., Kuhlmann, O., Lavé, T., Friberg, L. E., & Nielsen, E. I. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1856-x · Cited by 67
β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance
Jacobs, A., Taccone, F. S., Roberts, J. A., Jacobs, F., COTTON, F. J., Wolff, F., Créteur, J., Vincent, J., & Hites, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02534-17 · Cited by 65
Self-citationEmpiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
Liang, S. Y., & Kumar, A. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0493-6 · Cited by 76
Right Dose, Right Now: Customized Drug Dosing in the Critically Ill
Roberts, J. A., Kumar, A., & Lipman, J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002210 · Cited by 70
Self-citationRoggeveen, L. F., Guo, T., Fleuren, L. M., Driessen, R. H., Thoral, P., van Hest, R. M., Mathôt, R. A. A., Swart, E. L., de Grooth, H., van den Bogaard, B., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04098-7 · Cited by 64
Shulman, R. I., McKenzie, C., Landa, J., Bourne, R. S., Jones, A., Borthwick, M., Tomlin, M., Jani, Y. H., West, D., & Bates, I. P. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.04.008 · Cited by 64
“Each intervention was categorised by the clinical pharmacist into one of three groups: [1] medication error, [2] optimisation or [3] consult.”
Self-citationGatti, M., & Pea, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901574 · Cited by 65
“Consistently, the use of conventional dosing regimens may lead to failure in achieving even the most conservative PK/PD target in both RRT and nonRRT settings [16,17].”
BackgroundGatti, M., & Pea, F. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2169131 · Cited by 63
Bassetti, M., Welte, T., & Wunderink, R. G. (2016) · Critical Care · doi:10.1186/s13054-016-1197-5 · Cited by 69
“The DALI (Defining Antibiotic Levels in Intensive Care Patients) multinational ICU study was a pharmacokinetic point-prevalence study including eight systemically administered beta-lactam antibiotics [58].”
MethodSelf-citationKalın, G., Alp, E., Chouaikhi, A., & Roger, C. (2023) · Microorganisms · doi:10.3390/microorganisms11102575 · Cited by 66
Rhodes, N. J., Kuti, J. L., Nicolau, D. P., Wart, S. V., Nicasio, A. M., Liu, J., Lee, B. J., Neely, M. N., & Scheetz, M. H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01956-15 · Cited by 62
Ram, R., Halavy, Y., Amit, O., Paran, Y., Katchman, E. A., Yachini, B., Kor, S., Avivi, I. M., & Ben‐Ami, R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy258 · Cited by 65
Rational approach in the management of Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Russo, A., Croxatto, A., Calandra, T., & Guery, B. P. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000505 · Cited by 67
Self-citationSanz-Codina, M., Bozkır, H. Ö., Jorda, A., & Zeitlinger, M. A. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.018 · Cited by 64
PASCALE, G. D., Fortuna, S., Tumbarello, M., Cutuli, S. L., Vallecoccia, M. S., Spanu, T., Bello, G., Montini, L. M., Pennisi, M. A., Navarra, P., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3550-y · Cited by 60
Rizk, M. L., Bhavnani, S. M., Drusano, G. L., Dane, A. L., Eakin, A. E., Guina, T., Jang, S., Tomayko, J. F., Wang, J., Zhuang, L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02309-18 · Cited by 60
“(41) which found that ICU patients receiving -lactams who failed to achieve critical PK/PD targets were more likely to experience negative outcomes than those who achieved PK/PD targets.”
BackgroundOptimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time
Tilanus, A., & Drusano, G. L. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad305 · Cited by 67
“In 2014, Roberts et al [15] published their results of the DALI”
BackgroundMethodInfluentialDrug management in acute kidney disease – Report of the Acute Disease Quality Initiative XVI meeting
Ostermann, M., Chawla, L. S., Forni, L. G., Kane‐Gill, S. L., Kellum, J. A., Koyner, J. L., Murray, P. T., Ronco, C., Goldstein, S. L., & workgroup, A. 1. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13449 · Cited by 59
“Patients with impaired kidney function are particularly at risk for under- and over-dosing [2-4].”
Self-citationCarrié, C., Legeron, R., Petit, L., Ollivier, J., Cottenceau, V., d’Houdain, N., Boyer, P., Lafitte, M., Xuereb, F., Sztark, F., et al. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.08.026 · Cited by 59
“This β-Lactam antibiotic exhibits a time-dependent bacterial killing, such as optimal antimicrobial efficacy is achieved when the free drug concentration remains above the minimum inhibitory concentration (MIC) of the targeted organism(s) throughout the dosing interval (100%fTNMIC) [3].”
BackgroundPrevalence and Risk Factors for Augmented Renal Clearance in a Population of Critically Ill Patients
Baptista, J. P., Martins, P., Marques, M., & Pimentel, J. M. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618809688 · Cited by 58
“01 Admission days 9 (5-17) 9 (4-17) ns Fluid resuscitation on D1, mL 2155 (1844-2789) 1998 (1496-2500) <.”
BackgroundSelf-citationIndividualising Therapy to Minimize Bacterial Multidrug Resistance
Heffernan, A. J., Sime, F. B., Lipman, J., & Roberts, J. A. (2018) · Drugs · doi:10.1007/s40265-018-0891-9 · Cited by 63
Self-citationPharmacokinetics and Pharmacodynamics of Temocillin
Alexandre, K., & Fantin, B. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0584-7 · Cited by 57
“Nevertheless, wide variations of PK parameters (mainly on clearance and volume of distribution) were observed in ICU patients, as reported for other b-lactams in ICU patients [52].”
ResultAntimicrobial Stewardship Approaches in the Intensive Care Unit
Doernberg, S. B., & Chambers, H. F. “. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.002 · Cited by 60
Abate, S. M., Assen, S., Kebede, M. Y., & Basu, B. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102318 · Cited by 64
When and How to Use MIC in Clinical Practice?
Magréault, S., Jauréguy, F., Carbonnelle, É., & Zahar, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121748 · Cited by 62
“The use of recommended doses may be associated with sub-therapeutic exposure, particularly in intensive care patients [67].”
BackgroundInfluentialDomes, C., Domes, R., Popp, J., Pletz, M. W., & Frosch, T. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02422 · Cited by 55
Heil, E. L., Nicolau, D. P., Farkas, A., Roberts, J. A., & Thom, K. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01008-18 · Cited by 59
Self-citationPharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients
Stein, G. E., Smith, C. L., Scharmen, A., Kidd, J. M., Cooper, C., Kuti, J. L., Mitra, S., Nicolau, D. P., & Havlichek, D. H. (2018) · Surgical Infections · doi:10.1089/sur.2018.141 · Cited by 54
Bouglé, A., Dujardin, O., Lepère, V., Hamou, N. A., Vidal, C., Lebreton, G., Salem, J., El-Helali, N., Petijean, G., & Amour, J. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.02.015 · Cited by 58
Antibiotics in Necrotizing Soft Tissue Infections
Urbina, T., Razazi, K., Ourghanlian, C., Woerther, P., Chosidow, O., Lepeule, R., & de Prost, N. (2021) · Antibiotics · doi:10.3390/antibiotics10091104 · Cited by 57
“The results of the DALI study indeed support the conclusions that better outcomes for critically ill patients can be expected with higher drug exposures [63].”
BackgroundResultMobilizable antibiotic resistance genes are present in dust microbial communities
Maamar, S. B., Glawe, A. J., Brown, T. K., Hellgeth, N., Hu, J., Wang, J.-P., Huttenhower, C., & Hartmann, E. M. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008211 · Cited by 55
International survey of antibiotic dosing and monitoring in adult intensive care units
Williams, P. G., Tabah, A., Cotta, M. O., Sandaradura, I., Kanji, S., Scheetz, M. H., Imani, S., Elhadi, M. K., Luque, S., Schellack, N., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04527-1 · Cited by 56
“This target has been associated with improved clinical efficacy compared to lower drug exposure targets in patients with serious infections and is the supported PK/PD target in a recent international guideline for the management of sepsis and septic shock [4, 16].”
BackgroundSelf-citationCarrié, C., Chadefaux, G., Sauvage, N., de Courson, H., Petit, L., Nouette‐Gaulain, K., Pereira, B., & Biais, M. (2019) · Critical Care · doi:10.1186/s13054-019-2621-4 · Cited by 58
Benítez-Cano, A., Luque, S., Sorlí, L., Carazo, J., Ramos, I., Campillo, N., Curull, V., Sánchez‐Font, A., Vilaplana, C., Horcajada, J. P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2763-4 · Cited by 55
Roberts, J. A., Bellomo, R., Cotta, M. O., Koch, B. C. P., Lyster, H. S., Ostermann, M., Roger, C., Shekar, K., Watt, K., & Abdul-Aziz, M. H. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06847-2 · Cited by 53
Self-citationComprehensive guidance for antibiotic dosing in obese adults: 2022 update
Meng, L., Mui, E., Ha, D. R., Stave, C. D., Deresinski, S. C., & Holubar, M. K. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2769 · Cited by 51
Krapp, F., Grant, J. L., Sutton, S. H., Ozer, E. A., & Barr, V. O. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.01.018 · Cited by 51
Barreto, E. F., Rule, A. D., Voils, S. A., & Kane‐Gill, S. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2149 · Cited by 51
Principe, L., Lupia, T., Andriani, L., Campanile, F., Carcione, D., Corcione, S., Rosa, F. G. D., Luzzati, R., Stroffolini, G., Steyde, M., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15040463 · Cited by 54
Wong, J. L. C., David, S., Sanchez‐Garrido, J., Woo, J. Z., Low, W. W., Morecchiato, F., Giani, T., Rossolini, G. M., Beis, K., Brett, S. J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203593119 · Cited by 50
Self-citationMangalore, R. P., Peel, T. N., Udy, A. A., & Peleg, A. Y. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad223 · Cited by 58
Sime, F. B., Lassig‐Smith, M., Starr, T., Stuart, J., Pandey, S., Parker, S. L., Wallis, S. C., Lipman, J., & Roberts, J. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-19 · Cited by 51
Self-citationNew Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam
Lizza, B. D., Betthauser, K. D., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02318-20 · Cited by 53
Greppmair, S., Brinkmann, A., Roehr, A. C., Frey, O. R., Hagel, S., Dorn, C., Marsot, A., El‐Haffaf, I., Zöller, M., Saller, T., et al. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07154-0 · Cited by 49
“Standard doses of PIP have been reported to result in poor target attainment [14, 15].”
BackgroundThe Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
Barletta, J. F., Mangram, A. J., Byrne, M., Hollingworth, A. K., Sucher, J. F., Ali-Osman, F. R., Shirah, G. R., & Dzandu, J. K. (2016) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001211 · Cited by 49
“In one study that evaluated B-lactam antibiotic concentrations, only 80% of patients achieved the most conservative pharmacodynamic target and less than 50% achieved the preferred target.(3) Patients who failed to reach pharmacodynamic goals were 32% less likely to have a positive clinical outcome.”
BackgroundDhaese, S. A. M., Thooft, A. D. J., Farkas, A., Lipman, J., Verstraete, A., Stove, V. V., Roberts, J. A., & Waele, J. J. D. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.04.013 · Cited by 53
Self-citationWhat Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?
Chai, M. G., Cotta, M. O., Abdul-Aziz, M. H., & Roberts, J. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070638 · Cited by 51
Self-citationRoger, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.12.007 · Cited by 57
French Intensive Care Society, International congress – Réanimation 2016
Jaillette, E., Girault, C., Brunin, G., Zerimech, F., Chiche, A., Broucqsault-Dedrie, C., Fayolle, C., Minacori, F., Alves, I., Barrailler, S., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0114-z · Cited by 52
Self-citationon behalf of the TARGET Study Group, Hagel, S., Fiedler, S., Höhn, A., Brinkmann, A., Frey, O. R., Hoyer, H., Schlattmann, P., Kiehntopf, M., Roberts, J. A., et al. (2019) · Trials · doi:10.1186/s13063-019-3437-x · Cited by 51
Self-citationTherapeutic drug monitoring of β-lactam antibiotics in the ICU
Dhaese, S. A. M., Vooren, S. V., Boelens, J., & Waele, J. J. D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1788387 · Cited by 55
Gatti, M., & Pea, F. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000755 · Cited by 49
“com and clearance of hydrophilic agents, and this may be responsible for antibiotic underexposure and worsening in clinical outcome when conventional dosing regimens are administered [21,52].”
BackgroundPhe, K., Heil, E. L., & Tam, V. H. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa118 · Cited by 52
Gandia, P., Decheiver, S., Picard, M., Guilhaumou, R., Baklouti, S., & Concordet, D. (2023) · Antibiotics · doi:10.3390/antibiotics12030515 · Cited by 52
Roberts, J. A., Sime, F. B., Lipman, J., Hernández-Mitre, M. P., Baptista, J. P., Brüggemann, R. J. M., Darvall, J. N., Waele, J. J. D., Dimοpoulos, G., Lefrant, J., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07793-5 · Cited by 45
“Large multicenter studies such as the Defining Antibiotic Levels in Intensive Care Unit Patients (DALI) study provided valuable insights into antibacterial PK in critically ill patients but had sparse antifungal data across the 68 enrolling intensive care units (ICUs) [8, 9].”
Self-citationWilliams, P. G., Cotta, M. O., & Roberts, J. A. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693498 · Cited by 46
Self-citationAntón-Vázquez, V., Adjepong, S., Suarez, C., & Planche, T. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1654-9 · Cited by 46
Subtleties in practical application of prolonged infusion of β-lactam antibiotics.
De Waele, J. J., Lipman, J., Carlier, M., & Roberts, J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.01.007 · Cited by 44
“6% of patients treated with piperacillin or meropenem [4].”
BackgroundSelf-citationClinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
Bilal, M., Tabei, L. E., Büsker, S., Krauss, C., Fuhr, U., & Taubert, M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01063-5 · Cited by 45
“An fT > MIC of 50%, which is a typical target for other β-lactam antibiotics [37], might be insufficient in this case (Table 3).”
BackgroundPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients
Kees, M. G., Minichmayr, I. K., Moritz, S., Beck, S. M., Wicha, S. G., Kees, F., Kloft, C., & Steinke, T. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.600 · Cited by 44
Schoenenberger-Arnaiz, J. A., Ahmad-Diaz, F., Torner, M. M., Eroles, A. A., Cano-Marron, M., & Palomar, M. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2018-001713 · Cited by 44
Ollivier, J., Carrié, C., d’Houdain, N., Djabarouti, S., Petit, L., Xuereb, F., Legeron, R., Biais, M., & Breilh, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02134-18 · Cited by 44
Challenges and research priorities to progress the impact of antimicrobial stewardship
Bassetti, M., Giacobbe, D. R., Vena, A., & Brink, A. J. (2019) · Drugs in Context · doi:10.7573/dic.212600 · Cited by 45
Self-citationBao, H., Lv, Y., Wang, D., Xue, J., & Yan, Z. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2819-1 · Cited by 43
“A DALI study conducted across 68 hospitals revealed that infected critically ill patients may have adverse outcomes as a result of inadequate antibiotic exposure, and a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for thesemost seriously ill patients [31].”
BackgroundMasich, A. M., Heavner, M. S., Gonzales, J. P., & Claeys, K. C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0613-1 · Cited by 45
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
El‐Haffaf, I., Caissy, J.-A., & Marsot, A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01013-1 · Cited by 47
Heffernan, A. J., Lim, S. M. S., Lipman, J., & Roberts, J. A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100970 · Cited by 48
Self-citationBergen, P. J., Bulitta, J. B., Kirkpatrick, C. M. J., Rogers, K. E., McGregor, M. J., Wallis, S. C., Paterson, D. L., Nation, R. L., Lipman, J., Roberts, J. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02642-16 · Cited by 43
Self-citation
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.